Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: Results from a US database of over 45 000 HCV-infected, evaluated patients Academic Article uri icon

Overview

MeSH Major

  • Antiviral Agents
  • Hepatitis C, Chronic
  • Interferon-alpha
  • Polyethylene Glycols
  • Ribavirin

abstract

  • Approximately, 17% of HCV-infected patients in the general US population had at least one contraindication to PEG-IFN/RBV. Most contraindications were relative and potentially modifiable. Clinical assessment of contraindications as relative and/or modifiable should be considered and used to determine if patients could benefit from current PEG-IFN-containing triple therapy or future PEG-IFN- or RBV-free regimens.

publication date

  • February 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1111/apt.12200

PubMed ID

  • 23289640

Additional Document Info

start page

  • 473

end page

  • 81

volume

  • 37

number

  • 4